본문 바로가기
KERD
논문KCI 등재

Evidence Is Enough?: A Systematic Review and Network Meta- Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients

신인수|은성종|황보택근|김진욱|조영삼|김준철|김수진
대한배뇨장애요실금학회 (Korean Continence Society)|2017.04|International Neurourology Journal|제21권 제1호|pp. 29-37

0

조회

0

다운로드

5

인용

0

참고문헌

키워드

MenAsianDoseProstatic HyperplasiaTamsulosin

초록

Purpose: We compared the efficacy of tamsulosin between 0.2 mg and 0.4 mg in Asian prostatic hyperplasia (BPH) patients using network meta-analysis due to lack of studies with direct comparison. Methods: The literature search was conducted using the MEDLINE, Embase, and Cochrane Library. Keywords used were “BPH,” “tamsulosin,” “placebo.” Experimental groups were defined as tamsulosin 0.2 mg (Tam 0.2) and 0.4 mg (Tam 0.4) and common control group was defined as placebo for indirect treatment comparison. Mixed treatment comparison was performed including one direct comparison study. Results: Seven studies met the eligible criteria. Indirect treatment comparison revealed that total International Prostate Symptoms Score (IPSS) and quality of life score of IPSS were not significantly different in Tam 0.2 and Tam 0.4 (P>0.05). There was no significant difference of maximal flow rate and postvoid residual urine volume in Tam 0.2 and Tam 0.4 (P>0.05). Mixed treatment comparison including one direct comparison study showed inconsistency (P<0.001). Therefore, analysis using direct treatment comparison effect sizes of Tam 0.2 vs. placebo and Tam 0.4 vs. placebo was done and there was no significant difference. Conclusions: Network meta-analysis showed no difference of efficacy between tamsulosin 0.2 mg and 0.4 mg and the evidence of tamsulosin 0.4 mg as initial dose for Asian BPH patient seems to be insufficient. Therefore, initial dose of tamsulosin for Asian BPH patient should be 0.2 mg.

Abstract

Purpose: We compared the efficacy of tamsulosin between 0.2 mg and 0.4 mg in Asian prostatic hyperplasia (BPH) patients using network meta-analysis due to lack of studies with direct comparison. Methods: The literature search was conducted using the MEDLINE, Embase, and Cochrane Library. Keywords used were “BPH,” “tamsulosin,” “placebo.” Experimental groups were defined as tamsulosin 0.2 mg (Tam 0.2) and 0.4 mg (Tam 0.4) and common control group was defined as placebo for indirect treatment comparison. Mixed treatment comparison was performed including one direct comparison study. Results: Seven studies met the eligible criteria. Indirect treatment comparison revealed that total International Prostate Symptoms Score (IPSS) and quality of life score of IPSS were not significantly different in Tam 0.2 and Tam 0.4 (P>0.05). There was no significant difference of maximal flow rate and postvoid residual urine volume in Tam 0.2 and Tam 0.4 (P>0.05). Mixed treatment comparison including one direct comparison study showed inconsistency (P<0.001). Therefore, analysis using direct treatment comparison effect sizes of Tam 0.2 vs. placebo and Tam 0.4 vs. placebo was done and there was no significant difference. Conclusions: Network meta-analysis showed no difference of efficacy between tamsulosin 0.2 mg and 0.4 mg and the evidence of tamsulosin 0.4 mg as initial dose for Asian BPH patient seems to be insufficient. Therefore, initial dose of tamsulosin for Asian BPH patient should be 0.2 mg.

참고문헌 (24)

  1. Dunn CJ, "Tamsulosin : a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms", Drugs Aging, 19, pp.135~161 (2002)
  2. Wilde MI, "A review of its pharmacological properties and therapeutic potential in the management of symptomatic benign prostatic hyperplasia", Drugs, 52, pp.883~898 (1996)
  3. 김재헌, "Is Tamsulosin 0.2 mg Effective and Safe as a First-Line Treatment Compared with Other Alpha Blockers?: A Meta-Analysis and a Moderator Focused Study", Yonsei Medical Journal, 57(2), pp.407~418 (2016), 연세대학교의과대학[DOI]
  4. Shim SR, "General effect of low-dose tamsulosin (0.2 mg) as a first-line treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia:a systematic review and meta-analysis", Curr Med Res Opin, 31, pp.353~365 (2015)
  5. Kim KS, "Efficacy of dose escalation of tamsulosin for the treatment in symptomatic benign prostatic hyperplasia of lower urinary tract symptoms:a randomised, double-blind, phase 3 trial in Korean men", J Urol, 195(4 Suppl), pp.e466~ (2016)
  6. Moher D, "Preferred reporting items for systematic reviews and meta-analyses:the PRISMA statement", PLoS Med, 6, pp.e1000097~ (2009)
  7. Deeks JJ, "Systematic reviews in health care: meta-analysis in context", pp.285~312 (2001), BMJ Publishing Group
  8. Song F, "Validity of indirect comparison for estimating efficacy of competing interventions : empirical evidence from published meta-analyses", BMJ, 326, pp.472~ (2003)
  9. Nordling J., "Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia", BJU Int, 95, pp.1006~1012 (2005)
  10. Chapple CR, "Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia:results of an international, randomized, double-blind, placebo and active-controlled clinical trial performed in Europe", Eur Urol, 59, pp.342~352 (2011)
  11. Narayan P, "A second phase III multicenter placebo controlled study of 2 dosages of modified release tamsulosin in patients with symptoms of benign prostatic hyperplasia. United States 93-01 Study Group", J Urol, 160, pp.1701~1706 (1998)
  12. Oelke M, "Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial", Eur Urol, 61, pp.917~925 (2012)
  13. Lepor H., "Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group", Urology, 51, pp.892~900 (1998)
  14. Kawabe K, "Silodosin, a new alpha1A-adrenoceptor-selective antagonist for treating benign prostatic hyperplasia: results of a phase III randomized, placebo-controlled, double-blind study in Japanese men", BJU Int, 98, pp.1019~1024 (2006)
  15. Yokoyama O, "Tadalafil once daily for lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a randomized placebo-and tamsulosin-controlled 12-week study in Asian men", Int J Urol, 20, pp.193~201 (2013)
  16. Kawabe K, "Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group", J Urol, 144, pp.908~911 (1990)
  17. Lee E, "Clinical comparison of selective and non-selective alpha 1A-adrenoreceptor antagonists in benign prostatic hyperplasia : studies on tamsulosin in a fixed dose and terazosin in increasing doses", Br J Urol, 80, pp.606~611 (1997)
  18. Li NC, "Efficacy of low-dose tamsulosin in chinese patients with symptomatic benign prostatic hyperplasia", Clin Drug Investig, 23, pp.781~787 (2003)
  19. Park CH, "Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia : a nonblind multicentre korean study", Clin Drug Investig, 24, pp.41~47 (2004)
  20. Djavan B, "A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction", Eur Urol, 36, pp.1~13 (1999)
  21. 강동혁, "Analysis of Prescriptions of Alpha-Blockers and Phosphodiesterase 5 Inhibitors from the Urology Department and Other Departments", International Neurourology Journal, 15(4), pp.216~221 (2011), 대한배뇨장애요실금학회
  22. Choi H, "Assessment of tamsulosin 0.2 mg for symptomatic bladder outlet obstruction secondary to benign prostatic enlargement: data from a Korean multicenter cross-sectional study", Urol Int, 95, pp.50~55 (2015)
  23. Kim JW, "Efficacy of dose escalation of tamsulosin for the treatment of lower urinary tract symptoms", Low Urin Tract Symptoms, 4, pp.96~102 (2012)
  24. Kim JJ, "Efficacy and tolerability of tamsulosin 0.4 mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: a randomized placebo controlled trial", Int J Urol, 21, pp.677~682 (2014)

관련 논문AI추천

The Authors Reply: Reply on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”김수진, 김준철, 김진욱, 신인수, 은성종, 조영삼, 황보택근대한배뇨장애요실금학회 · International Neurourology Journal2017 · 제21권 제3호Letter to the Editor: Commentary on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”최훈, 배재현, 태범식대한배뇨장애요실금학회 · International Neurourology Journal2017 · 제21권 제3호A Prospective, Multicenter, Open-Label Study of Dose Escalation Therapy in Male Patients With Nocturia Refractory to 0.2-mg Tamsulosin MonotherapyHo Song Yu, Jeong Woo Lee, Jihyeong Yu, Min Chul Cho, Sung Yong Cho대한배뇨장애요실금학회 · International Neurourology Journal2019 · 제23권 제4호Beta 3 Adrenoreceptor Agonist for the Management of Lower Urinary Tract Symptoms in Men With Benign Prostatic Hyperplasia: A Systematic Review강태욱, 김명하, 김수진, 정재흥대한배뇨장애요실금학회 · International Neurourology Journal2021 · 제25권 제3호Meta-Analysis of the Efficacy and Safety of Imidafenacin for Overactive Bladder Induced by Benign Prostatic Hyperplasia in Men Receiving Alpha-Blocker TherapyLiye Liang, Ning Wang, Tong Cai, Yong Zhang, Yuanshan Cui, Zhongbao Zhou대한배뇨장애요실금학회 · International Neurourology Journal2020 · 제24권 제4호Impact of Intravesical Protrusion of the Prostate in the Treatment of Lower Urinary Tract Symptoms/Benign Prostatic Hyperplasia of Moderate Size by Alpha Receptor Antagonist김형지, 서유미대한배뇨장애요실금학회 · International Neurourology Journal2012 · 제16권 제4호

이 간행물의 다른 논문 (19건)

A Clinician’s Perspective on the Mechanism of β3-Adrenoceptor Agonists in the Bladder이택pp. 1-2Collaborative Efforts Among the Fields of Technology, Device Development, and Medicine이택pp. 1-1New Equipment and Devices for Therapeutic Purpose신관우pp. 2-3Broaden and Build Up Knowledge Based on Investigative and Clinical Research김계환pp. 3-5Applications of Microfluidic Devices for Urology박헌국, 김경숙, 한세직pp. 4-9
원문 보기